GoKawiil
Tech News
Boston Longevity Week, an 11-day series of events including biomarker conferences, an AI hackathon and an investor pitch night with over 30 venture firms, culminates in a Translational Longevity Summit. The event's organizers argue the longevity field's core challenge isn't a lack of innovation or even regulation, but a failure to translate promising research into validated, clinically usable treatments.
Researchers report findings on biological markers that correlate with improved patient outcomes when immune-based therapies are used before and after surgery for lung cancer. The publication, appearing on Nature's platform, outlines how certain biomarkers may help predict which patients respond best to this perioperative treatment approach.
The American Psychiatric Association has announced it will revise the Diagnostic and Statistical Manual of Mental Disorders, aiming to incorporate biological measures into future diagnostic criteria for the first time. A strategic subcommittee, which included the author, has been working since 2024 to determine how neurobiology and biomarkers—such as blood tests and imaging scans—could supplement or refine existing symptom-based diagnoses. The current DSM-5, published in 2013, has faced criticism for relying solely on behavioral symptoms without objective biological measures.
The FDA has approved PrecivityAD2, a blood test that detects amyloid and tau biomarkers linked to Alzheimer's disease in symptomatic patients starting at age 40. In a validation study of 1,142 adults, the test correctly identified positive biomarkers 97.6% of the time, even among patients with conditions like kidney disease or diabetes that can otherwise skew results.